Xu Huimin, M.S.

Department:Pharmacy

Position:Vice Chair of Pharmacy

Medical School:Zhejiang University School of Medicine, China

Academic Rank:Chief Pharmacist

Clinical / Research Interests

Clinical pharmacology, drug utilization, comprehensive medication management for patients with cardiovascular disease.

Professional Highlights

National Excellent Clinical Pharmacist, 2018

Professional Appointments

Vice Chairman, Youth Working Committee, Society of Hospital Pharmacy, Zhejiang Pharmaceutical Association

Vice Chairman, Youth Committee, Clinical Pharmacy Branch, Zhejiang Medical Association

Education Experience

Research Summary

Pharmacotherapy for cardiovascular disease and cerebral injury.

Publications

Xu H, Ping Y, Lin H, He P, Li W, Dai H. Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up. Transl Stroke Res. 2017 Jun;8(3):228-233.

Xu H, Cai S, Dai H. Characteristics of Infective Endocarditis in a Tertiary Hospital in East China. PLoS One. 2016 Nov 18;11(11):e0166764.

Xu J, Zhang M, Ni Y, Shi J, Gao R, Wang F, Dong Z, Zhu L, Liu Y, Xu H*. Impact of low hemoglobin on the development of contrast-induced nephropathy: A retrospective cohort study. Exp Ther Med. 2016 Aug;12(2):603-610.

Xu H, He Y, Xu L, Yan X, Dai H. Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data. Int J Clin Pharmacol Ther. 2015 Jun;53(6):430-7. 

Xu HM, Cai HW. Clinical Research Progress of Anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Monoclonal Antibodies. Chin Pharm J, 2015, 50(16):1375-1379.

Shi JN, Xu HM*. Moxifloxacin Induced Seizures -A Case Report. Iranian J Publ Health, 2014, 43(9):1291-1294.

Xu HM, Cai HW, Dai HB, Yan XF, Zhou Q, Xu G, Huang ZQ, Mao W. Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: a Chinese medicine hospital versus a general hospital. Chin J Integr Med. 2014 May;20(5):375-80. 

Cai H, Xu H*. Use of nonsteroidal antiinflammatory drugs in patients with cardiovascular disease. Chin Pharm J, 2014, 49(6):512-516.

Qian ZS, He YN, Zhang L, Wang LF, Liu NN, Zhou HY, Yang HC, Xu HM*. Investigation of anticoagulation intensity of warfarin in inpatients. Journal of Clincal Cardiology (China), 2014, 30(5):424-427.

Cai H, Dai H, Hu Y, Yan X, Xu H*. Pharmacist care and the management of coronary heart disease: a systematic review of randomized controlled trials. BMC Health Serv Res. 2013 Nov 4;13:461. 

Xu H, Cai H, Qian Z, Xu G, Yan X, Dai H. Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective study in a Chinese teaching hospital. BMC Cardiovasc Disord. 2012 Dec 5;12:118.

Xu HM, Chen Y, Xu J, Zhou Q. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol. 2012 Nov 7;18(41):5972-8.

Cai HW, Xu HM*, He YN, Dai HB, Yu LY, Yan XF. Meta-analysis: Effect of Monotherapy and Combination Therapy with Sucralfate and Acid Secretion Inhibitor. Chin JMAP, 2012, 29(9):852-857.

Xu HM, Cai HW, Li TY, Wei EQ. Progress of studies of sulfonamide cross-reactivity. Chin J Pharmacol Toxicol, 2012, 26(6):897-902.

Xu H, Yao H, Weng J, Xu X. Effects of Chuankezhi injection on airway inflammation in mouse model of asthma and isolated guinea-pig airway smooth muscle. Chin J Chin Materia Medica. 2010 May;35(10):1302-6.

Xu HM, Xu X. Prescription analysis of celecoxib in outpatients of a general hospital. Chin Pharm J, 2009, 44(20):1596-1598.

Xu HM, Ye YL, Shi WZ, Chen LP, Zhang WP, Wei EQ. Protective effect of cilostazol on persistent focal cerebral ischemia in mice. Chin J New Drugs, 2007, 16(12):947-950.

Xu HM, Wei EQ, Zhang SH, Zhu ZY, Yu GL, Zhang Q, Chu SL. Macrophotographic measurement of brain surface area for evaluating brain edema after focal cerebral ischemia in mice. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2003 Dec;32(6):492-6.


Current Program

The effect of annexin A2 on blood brain barrier integrity after brain ischemia and its regulation mechanisms. Funding Source: Natural Science Foundation of Zhejiang Province.

The effect of IKKβ pathway of mast cells in cerebral ischemic injury. Funding Source: National Natural Science Foundation of China.


Find People

Search by Family Name

Find A Department

Search by Departments